Lung cancer trials in Italy

In Italy 272 Also abroad 2746

272 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 14 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Where
Bergamo, Milan, Naples, Perugia, Siena
Age
18 years and over
People
254 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07492680
No phaseNot yet taking people in Italy
Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers
Where
Milan
Age
18 years and over
People
360
Run by
European Institute of Oncology
See details and how to joinNCT07815873
Phase 3Taking people
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
Where
Aviano, Catania, Firenze, Medolo, Ravena, Reggio Emilia, Azienda Ospedaliero Universitaria di Bologna - Policlinico S. Orsola-Malpighi, Azienda USL Toscana Sud Est -Ospedale Misericordia - Grosseto, Azienda Ospedaliero-Universitaria di Modena (AOU Modena) - Policlinico di Modena, Azienda Ospedaliera San Gerardo - Monza, Azienda Ospedaliero - Universitaria di Parma, IRCCS Istituti Fisioterapici Ospitalieri- Istituto Nazionale tumori Regina Elena, Azienda Ospedaliera Universitaria Senese - (ITT) - Center for Immuno-Oncology (CIO), La Maddalena Casa di Cura di Alta Specialita - Palermo
Age
18 years and over
People
65 worldwide
Run by
Dizal Pharmaceutical Co. Ltd.
See details and how to join2022-502959-54-00
Phase 2Taking people
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Where
Genoa, Milan, Monza, Naples
Age
18 years and over
People
520 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05498428 · EU 2023-505065-91-00
Phase 3Taking people
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Where
Bari, Bergamo, Catanzaro, Florence, Meldola, Milan, Rome, Udine
Age
18 years and over
People
614 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00
Phase 2Taking people
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Where
Orbassano, Padova, Ravenna, Rome, Rozzano
Age
18 years and over
People
480 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06667076 · EU 2025-520730-28-00
No phaseTaking people
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
Where
Avellino, Aviano, Bari, Bergamo, Brescia, Candiolo, Catania, Catanzaro, Genova, Lecce, Milan, Monza, Naples, Novara, Olbia, Orbassano, Palermo, Parma, Pisa, Ravenna, Roma, Rome, Sassari, Torrette-Ancona, Urbino
Age
18 years and over
People
380 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07230691
Phase 2Taking people
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Where
Candiolo, Meldola, Milan, Naples, Orbassano, Padova, Parma, Ravenna, Rome
Age
18 years and over
People
240 worldwide
Run by
Genmab
See details and how to joinNCT07288177 · EU 2025-522107-18-00
Phase 2/3Taking people
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Where
Ancona, Aviano, Genoa, Milan, Naples, Peschiera del Garda, Rome, Siena
Age
18 years and over
People
750 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT07365319 · EU 2025-525013-23-00
Phase 2/3Taking people
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Where
Avellino, Aviano, Bergamo, Bologna, Candiolo, Catania, Cremona, Ferrara, Lucca, Meldola, Milan, Misterbianco, Naples, Orbassano, Pavia, Peschiera del Garda, Rome, Siena, Udine
Age
18 years and over
People
1,580 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00
Phase 3Taking people
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
Where
Alexandria, Brescia, Camaiore, Catania, Ferrara, Genoa, Lucca, Meldola, Milan, Pavia, Perugia, Peschiera del Garda, Ravenna, Reggio Emilia, Rome, Siena, Terni
Age
18 years to 90 years
People
507 worldwide
Run by
ImmunityBio, Inc.
See details and how to joinNCT06745908 · EU 2025-521221-32-00
Phase 3Taking people
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Where
Aviano, Milan
Age
18 years and over
People
480 worldwide
Run by
ArriVent BioPharma, Inc.
See details and how to joinNCT07185997
Phase 3Taking people
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Where
Bari, Milan, Misterbianco, Naples, Orbassano, Rome, Rozzano, Verona
Age
18 years and over
People
400 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00
No phaseTaking people
Patient Needs and Preferences for NSCL Cancer Treatment Monitoring
Where
Milan
Age
18 years and over
People
35
Run by
European Institute of Oncology
See details and how to joinNCT07909343
Phase 2/3Taking people
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Where
Bari, Bologna, Brescia, Candiolo, Florence, Genoa, Meldola, Milan, Monza, Naples, Padova, Parma, Perugia, Pesaro, Ravenna, Rome, Varese
Age
18 years and over
People
626 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00
Phase 1Taking people
Phase 1 Study of MK-1084 in KRAS mutant advanced solid tumors
Where
Naples, Rozzano, Siena
Age
18 years and over
People
214 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT05067283 · EU 2022-501563-40-00
Phase 1/2Taking people
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Where
Naples, Orbassano, Rome, Rozzano
Age
18 years and over
People
345 worldwide
Run by
Pierre Fabre Medicament
See details and how to joinNCT06043817 · EU 2023-506759-51-00
Phase 1/2Taking people
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Where
Florence, Milan, Rome
Age
18 years and over
People
450 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04165070 · EU 2023-506932-33-00
No phaseTaking people
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Where
Florence, Milan, Roma
Age
18 years and over
People
1,065 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04165798
Phase 3Taking people
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Bari, Cremona, Milan, Misterbianco, Naples, Perugia, Rome, Varese
Age
18 years and over
People
768 worldwide
Run by
AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00
Phase 1/2Taking people
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Where
Aviano, Catania, Genoa, Meldola, Milan, Orbassano, Pavia, Ravenna, Rome
Age
18 years and over
People
364 worldwide
Run by
Synthekine
See details and how to joinNCT05098132 · EU 2025-522632-14-00
Phase 3Taking people
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Where
Brescia, Genoa, Milan, Monza, Naples, Novara, Pavia, Rome, Rozzano, Verona
Age
18 years and over
People
851 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Where
Florence, Leghorn, Legnano, Monza, Orbassano, Padova, Peschiera del Garda, Rome
Age
18 years and over
People
1,160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00
Phase 2Taking people
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Where
Bergamo, Brescia, Ferrara, Florence, Milan, Modena, Pavia, Verona
Age
18 years and over
People
750 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00
Phase 2Taking people
A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR mutations
Where
Arezzo, Bari, Camaiore, Catania, Civitavecchia, Florence, Genoa, Lucca, Macerata, Meldola, Messina, Modena, Naples, Padova, Palermo, Pavia, Piacenza, Reggio Emilia, Rionero In Vulture, Rome, Saronno, Sassari, Teramo, Terni, Trento, Trieste, Varese, Verona, FONDAZIONE GIOVANNI PAOLO II - Gemelli Molise, IRCCS Istituti Fisioterapici Ospitalieri- Istituto Nazionale tumori Regina Elena, Azienda USL Toscana Sud Est -Ospedale Misericordia - Grosseto, A.O.U Maggiore della Carità
Age
18 years and over
People
189 worldwide
Run by
Fondazione Ricerca Traslazionale
See details and how to joinNCT04811001 · EU 2024-518223-29-00